Page last updated: 2024-08-26

sr141716 and Body Weight

sr141716 has been researched along with Body Weight in 118 studies

Research

Studies (118)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.69)	18.2507
2000's	66 (55.93)	29.6817
2010's	47 (39.83)	24.3611
2020's	3 (2.54)	2.80

Authors

Authors	Studies
Chen, J; Doss, GA; Finke, PE; Fong, TM; Lao, JZ; Mills, SG; Plummer, CW; Schaeffer, MT; Shearman, LP; Shen, CP; Strack, AM; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J	1
Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z	1
Feng, Y; Fong, TM; Goulet, MT; Hagmann, WK; Jewell, JP; Kumar, S; Lanza, TJ; Lao, J; Lin, LS; Liu, P; Marsh, DJ; Qi, H; Rosko, K; Samuel, K; Shah, SK; Shearman, LP; Shen, CP; Strack, A; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J; Xiao, JC; Xu, SS; Yin, W	1
Achebe, F; Akuche, C; Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Smith, RA; Su, N; Taing, C; Tomlinson, S; Tritto, T; Wang, G; Wirtz, SN; Wong, W; Yang, XF; Ying, S; Zhang, Z	1
Gandhi, N; Gite, A; Goswami, A; Jain, MR; Joharapurkar, A; Mishra, B; Pandey, B; Patel, H; Patel, JZ; Patel, PR; Raval, P; Raval, S; Sadhwani, N; Solanki, M; Soni, R; Srivastava, BK	1
Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P	1
Duranti, A; LoVerme, J; Mor, M; Piomelli, D; Rivara, S; Spadoni, G; Stella, N; Tarzia, G; Tontini, A; Xu, C	1
Erdélyi, P; Fischer, J; Gyertyán, I; Hegyi, E; Kiss, B; Laszy, J; Páyer-Lengyel, D; Szabó, G; Szemzo, A; Szikra, J; Varga, B; Vastag, M; Vukics, K	1
Bjurling, E; Cooper, M; Högberg, T; Linget, JM; Murray, A; Nielsen, PA; Nørregaard, PK; Receveur, JM	1
Balasubrahmanyam, D; Chaudhury, H; Jadhav, VP; Kannan, M; Khan, SK; Mohan, P; Nadipalli, P; Nanduri, S; Neelima Devi, B; Nyavanandi, VK; Rawoof, KA; Sasmal, PK; Sebastian, VJ; Shiva Kumar, K; Srinivas, P; Srinivasa Reddy, D; Swetha, J; Talwar, R; Venkatesham, B	1
Avraham, Y; Berry, EM; Ezra, AF; Grigoriadis, NC; Harfoush, F; Katzhendler, J; Kunkes, E; Listman, C; Merchavia, S; Najajreh, Y; Salameh, S; Vorobeiv, L	1
Bednarski, M; Bresinsky, M; Elz, S; Höring, C; Karcz, T; Kieć-Kononowicz, K; Kotańska, M; Kuder, KJ; Latacz, G; Mika, K; Mönnich, D; Nagl, M; Pockes, S; Podlewska, S; Seibel, U; Siwek, A; Stark, H; Szczepańska, K	1
Abdalla, J; Cinar, R; Coffey, NJ; Hassan, SA; Iyer, MR; Katz, A; Kim, KA; Lee, YS; Liu, Z; Wood, CM; Zawatsky, CN	1
Blumen, T; Brake, R; Cohen, Y; Ferreira, S; Kolodziej, A; Morningstar, M	1
Chen, B; Hu, N	1
Cottone, P; Mancino, S; Moore, CF; Sabino, V; Schlain, GS	1
Agbemenyah, H; Beißbarth, T; Del Río, JA; Di Marzo, V; Gil, V; Havemann-Reinecke, U; Hoyer-Fender, S; Lorenzen, S; Moore, TP; Piscitelli, F; Pommerenke, C; Quintana, E; Ramió-Torrentà, LL; Salinas, G; Tomas-Roig, J	1
Fu, L; Gu, CW; Han, JH; Wei, LW; Yuan, ZQ; Zhao, MD	1
de La Serre, CB; Grunewald, ZI; Kirkland, R; Lee, S; Ross, M	1
Hegele, RA; Lazarte, J	1
Cottone, P; Dore, R; Rice, KC; Sabino, V; Valenza, M; Wang, X	1
Casu, MA; Lazzari, P; Marcello, S; Mastinu, A; Murineddu, G; Pinna, GA; Pira, M; Pisu, C; Reali, R	1
Blasio, A; Cottone, P; Di Marzo, V; Iannotti, FA; Iemolo, A; Orlando, P; Petrosino, S; Rice, KC; Sabino, V; Steardo, L; Zorrilla, EP	1
Bhanot, S; Chakravarty, K; Manchem, VP; McCaleb, ML; Monia, BP; Watts, LM; Yu, XX	1
Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Kunos, G; Szanda, G; Tam, J; Zhou, L	1
Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK	1
Carlsson, B; Hansson, GI; Hjorth, S; Karlsson, C; Karpefors, M	1
Li, H; Reichenbach, ZW; Tuma, RF; Ward, SJ	1
Noll, G; Périat, D; Sudano, I	1
Michaelides, M; Piyis, YK; Ramalhete, RC; Thanos, PK; Volkow, ND; Wang, GJ	1
Chevalier, S; Hollander, P; Iranmanesh, A; Rosenstock, J	1
Caldwell, C; Fekete, C; Klein, M; Liposits, Z; Nogueiras, R; Reizes, O; Rohner-Jeanrenaud, F; Suchanek, PM; Tschöp, J; Tschöp, MH; Veyrat-Durebex, C; Watanabe, M; Wittmann, G; Woods, SC	1
Bennetzen, MF; Nielsen, MP; Pedersen, SB; Richelsen, B	1
Atkinson, RD; DeLeve, LD; Kanel, GC; McCuskey, RS; Wang, X	1
Rapezzi, C; Volpe, M	1
Huskinson, SL; Rasmussen, EB	1
Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A	1
Awazawa, M; Hasegawa, C; Iwabu, M; Kadowaki, T; Katsuyama, H; Kubota, N; Kubota, T; Moroi, M; Nagai, R; Noda, T; Ohsugi, M; Sugi, K; Takamoto, I; Terauchi, Y; Tobe, K; Tokuyama, K; Ueki, K; Watanabe, T; Yamauchi, T	1
Galzin, AM; Hall, D; Minehira, K; Poussin, C; Tarussio, D; Thorens, B	1
Allen, AM; Oldfield, BJ; Verty, AN	1
Alméras, N; Boka, G; Després, JP; Lemieux, I; Ross, R	1
Taskinen, MR	1
Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET	1
Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Kabir, M; Kim, SP; Kolka, C; Lottati, M; Mooradian, V; Richey, JM; Stefanovski, D; Woolcott, OO; Zheng, D	1
Delafoy-Plasse, L; Delion, V; Duvivier, VF; Galzin, AM; Guillot, E; Le Bail, JC; Lechevalier, P; Pruniaux, MP	1
Rasmussen, EB; Wakley, AA	1
Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES	1
Bloks, VW; Jonas, I; Koolman, AH; Kuipers, F; Oosterveer, MH; Sauer, PJ; van Dijk, G	1
Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Patel, PR; Sharma, M; Singh, S	1
Cheung, BM; Li, M	1
Berrendero, F; Burokas, A; Gispert, JD; Heyne, A; Kiesselbach, C; Maldonado, R; Martín, M; Martín-García, E; Millán, O; Rubí, B	1
Lockney, J; Maldonado, R; Oveisi, F; Piomelli, D; Touriño, C	1
Degrace, P; Demizieux, L; Djaouti, L; Gresti, J; Jourdan, T; Vergès, B	1
Cohen, SB; DiPetrillo, K; Xu, L; Zhang, Y	1
Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS	1
Diane, A; Kelly, SE; Mangat, R; Novak, S; Proctor, SD; Russell, JC; Vine, DF; Wang, Y	1
Aguirre, CA; Castillo, VA; Llanos, MN; Ronco, AM; Valenzuela, CA	1
Patti, ME	1
Hansen, HS; Johansen, T; Malmlöf, K; Mølhøj, S; Schweiger, M; Zimmermann, R	1
de Sotomayor, MA; Herrera, MD; Marhuenda, E; Mingorance, C	1
Delis, F; Gopez, V; Grandy, DK; Kunos, G; Michaelides, M; Thanos, PK; Volkow, ND; Wang, GJ	1
Cabasino, S; Lazzari, P; Manca, I; Mastinu, A; Pani, L; Sanna, A	1
Cahill, K; Ussher, MH	1
Bennetzen, MF	1
Bouwman, J; Hankemeier, T; Havekes, LM; Hu, C; Reijmers, TH; Spijksma, G; van den Hoek, AM; van der Greef, J; van der Heijden, R; Verheij, E; Wang, M; Wei, H; Wopereis, S; Xu, G	1
Cavallo, JS; Chain, DC; Dressler, HM; Economides, KD; Fan, C; Favara, SG; Galzin, AM; Guillot, E; Naimi, S; Palejwala, VA; Pang, Z; Polites, HG; Pruniaux, MP; Schaffer, E; Tocci, MJ; Weinstock, D; Wu, NN; Yamdagni, P; Zhang, X; Zhao, W	1
Bornstein, SR; Chavakis, T; Lamounier-Zepter, V; Schindler, C	1
Chaudhary, N; Czyzyk, TA; Lockie, SH; Oldfield, BJ; Perez-Tilve, D; Statnick, MA; Tschöp, MH; Woods, SC	1
Fride, E; Pinhasov, A; Schechter, M; Weller, A	1
Antunes-Rodrigues, J; de Carvalho Borges, B; Elias, LL; Reis, WL; Rorato, R	1
Bouwman, J; Hankemeier, T; Havekes, LM; Hu, C; Korthout, HA; Ramaker, R; Reijmers, TH; van den Hoek, AM; van der Greef, J; Vennik, M; Verheij, ER; Wang, M; Wei, H; Witkamp, RF; Wopereis, S; Xu, G	1
Adams, SA; Bradshaw, HB; Demas, GE; Ho, JM; Smith, NS	1
Lockie, SH; Oldfield, BJ; Stefanidis, A; Verty, AN	1
Essawy, S; Zaitone, SA	1
Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M	1
Donato, J; Economides, K; Elias, CF; Elmquist, JK; Gautron, L; Pierpont, S; Rossi, J; Scott, M; Vianna, CR	1
Rodgers, RJ; Wright, FL	1
Ball, MP; Buchanan, RW; Conley, RR; Feldman, S; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Warren, KR	1
Antunes-Rodrigues, J; Elias, LL; Miyahara, C; Rorato, R	1
Arnone, M; Delgorge, C; Gonalons, N; Keane, P; Maffrand, JP; Ravinet Trillou, C; Soubrie, P	1
Bensaid, M; Esclangon, A; Gary-Bobo, M; Le Fur, G; Maffrand, JP; Oury-Donat, F; Soubrié, P	1
Fernández-Frutos, B; González, R; Martínez-Orgado, J; Romero, E; Romero, J; Urigüen, L; Viveros, MP	1
Arnone, M; Delgorge, C; Menet, C; Ravinet Trillou, C; Soubrié, P	1
Connoley, IP; Liu, YL; Stock, MJ; Wilson, CA	1
Abel, N; Avraham, Y; Berry, EM; Mechoulam, R; Menachem, AB; Okun, A; Zlotarav, O	1
Böcking, W; Bramlage, P; Kirch, W; Mueller, EA	1
Carai, MA; Colombo, G; Gessa, GL	1
DiPatrizio, NV; Järbe, TU	1
Gardner, A; Mallet, PE	1
Benwell, KR; Clifton, PG; Kennett, GA; Misra, A; Revell, DF; Sellwood, DM; Thornton-Jones, ZD; Vickers, SP	1
Carai, MA; Colombo, G; Gessa, GL; Maccioni, P	1
Evenden, J; Ko, T	1
Croci, T; Zarini, E	1
Hillard, CJ; Rademacher, DJ	1
Bifulco, M; Gazzerro, P; Grimaldi, C; Pisanti, S; Santoro, A	1
Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC	1
Hohmann, AG; Makriyannis, A; Rahn, EJ	1
Cahill, K; Ussher, M	2
Jensen, MD	1
Braun, H; Fride, E; Matan, H; Reggio, PH; Seltzman, HH; Steinberg, S	1
Calabro, S; Kelsey, JE	1
Barbosa, I; Bidouard, JP; Cadrouvele, C; Dedio, J; Gouraud, L; Herbert, JM; Janiak, P; Le Fur, G; Maffrand, JP; O'Connor, S; Pierre, F; Poirier, B	1
Carrión, AM; Delgado-García, JM; Fontanella, GH; Sáez-Cassanelli, JL	1
Bourson, A; Fisseha, M; Kunz, I; Meier, MK; Schilling, W	1
Elvert, R; Haschke, G; Herling, AW; Kilp, S; Kramer, W	1
Aronne, LJ; Neff, LM	1
Blundell, JE; Rodgers, RJ; Tallett, AJ	1
Ferrara, M; Mathes, CM; Rowland, NE	1
Di Marzo, V; Szallasi, A	1
Fehr, C; Gann, H; Koller, G; Lesch, OM; Leweke, M; Mann, KF; Schmidt, P; Soyka, M	1
Aceto, MD; Lowe, JA; Martin, BR; Scates, SM	1
Hanoune, J; Hutcheson, DM; Maldonado, R; Roques, BP; Smadja, C; Tzavara, ET; Valjent, E	1
Maldonado, R; Valjent, E; Valverde, O; Zimmer, A; Zimmer, AM	1
Aceto, MD; Martin, BB; Scates, SM	1
De Witte, PH; Lallemand, F; Soubrié, PH	1

Reviews

14 review(s) available for sr141716 and Body Weight

Article	Year
Cannabis effects on lipoproteins. Current opinion in lipidology, 2019, Volume: 30, Issue:2 Topics: Anti-Obesity Agents; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cannabis; Case-Control Studies; Cholesterol, HDL; Energy Intake; Gene Expression; Humans; Lipid Metabolism; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides	2019
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult	2009
Cannabinoid type 1 receptor antagonists for smoking cessation. The Cochrane database of systematic reviews, 2011, Mar-16, Issue:3 Topics: Amides; Body Weight; Humans; Piperidines; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention	2011
Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options. Danish medical bulletin, 2011, Volume: 58, Issue:4 Topics: Adiponectin; Adipose Tissue; Animals; Body Mass Index; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Case-Control Studies; Endocannabinoids; Fatty Acids, Nonesterified; Feeding Behavior; Female; Genetic Variation; Humans; Inflammation; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reference Values; Rimonabant; Risk Factors; Weight Loss	2011
[Pharmacological concepts for the treatment of obesity - a therapeutic meander?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:31-32 Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Body Weight; Brain; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Drug Approval; Drug Combinations; Drug Recalls; Drugs, Investigational; Forecasting; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2011
[Innovation instead of imitation -- news in drug therapy]. Deutsche medizinische Wochenschrift (1946), 2005, Apr-01, Volume: 130, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Anticoagulants; Antineoplastic Agents; Azetidines; Body Weight; Cannabinoid Receptor Antagonists; Cetuximab; Drug Therapy; Ezetimibe; Fondaparinux; Humans; Hypoglycemic Agents; Insulin; Osteoporosis, Postmenopausal; Piperidines; Polysaccharides; Pyrazoles; Rimonabant; Smoking Cessation; Teriparatide; Thromboembolism	2005
Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life sciences, 2005, Sep-23, Volume: 77, Issue:19 Topics: Animals; Body Weight; Cannabinoids; Eating; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders	2005
[Rimonabant reduced body weight and blood sugar]. Medizinische Monatsschrift fur Pharmazeuten, 2005, Volume: 28, Issue:8 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Clinical Trials as Topic; Humans; Hypoglycemic Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2005
Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS drug reviews, 2006,Summer, Volume: 12, Issue:2 Topics: Animals; Body Weight; Drug Evaluation, Preclinical; Eating; Humans; Pharmacology, Clinical; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2006
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Anti-Obesity Agents; Antineoplastic Agents; Body Weight; Humans; Neurodegenerative Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Substance-Related Disorders	2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide	2007
What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management? The American journal of medicine, 2007, Volume: 120, Issue:9 Suppl 1 Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Waist-Hip Ratio	2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide	2007
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms	2007

Trials

6 trial(s) available for sr141716 and Body Weight

Article	Year
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes care, 2008, Volume: 31, Issue:11 Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome	2008
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:16 Topics: Blood Pressure; Body Mass Index; Body Weight; Cardiovascular System; Female; Fenofibrate; Heart; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Time Factors; Waist Circumference	2008
Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3 Topics: Adiponectin; Adiposity; Adult; Anti-Obesity Agents; Apolipoproteins; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Intra-Abdominal Fat; Lipoproteins, LDL; Liver; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triglycerides	2009
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:4 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant	2009
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1 Topics: Adult; Antipsychotic Agents; Appetite Depressants; Body Mass Index; Body Weight; Brain; Cannabinoid Receptor Antagonists; Double-Blind Method; Drug Inverse Agonism; Eating; Energy Intake; Female; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Satiety Response; Schizophrenia; Schizophrenic Psychology; Signal Transduction; Treatment Outcome	2013
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Alcoholism; Body Mass Index; Body Weight; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Treatment Outcome	2008

Other Studies

98 other study(ies) available for sr141716 and Body Weight

Article	Year
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorganic & medicinal chemistry letters, 2005, Mar-01, Volume: 15, Issue:5 Topics: Animals; Area Under Curve; Binding, Competitive; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Eating; Humans; Imidazoles; Molecular Structure; Obesity; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship	2005
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives. Bioorganic & medicinal chemistry letters, 2007, Feb-01, Volume: 17, Issue:3 Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain	2007
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Journal of medicinal chemistry, 2006, Dec-28, Volume: 49, Issue:26 Topics: Animals; Anti-Obesity Agents; Body Weight; Cannabinoids; Cyclic AMP; Eating; Humans; Liver; Microsomes; Obesity; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2	2006
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity. Bioorganic & medicinal chemistry letters, 2007, May-15, Volume: 17, Issue:10 Topics: Animals; Anti-Obesity Agents; Body Weight; Dose-Response Relationship, Drug; Imidazoles; Obesity; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Structure-Activity Relationship	2007
Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. Journal of medicinal chemistry, 2007, Nov-29, Volume: 50, Issue:24 Topics: Amides; Animals; Anti-Obesity Agents; Appetite Depressants; Body Weight; Female; Models, Molecular; Morpholines; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Stereoisomerism; Structure-Activity Relationship; Sulfonamides	2007
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. Journal of medicinal chemistry, 2008, Apr-10, Volume: 51, Issue:7 Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship	2008
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorganic & medicinal chemistry letters, 2009, Feb-01, Volume: 19, Issue:3 Topics: Animals; Anti-Obesity Agents; Benzyl Compounds; Body Weight; Cannabinoids; Cerebellum; Chemistry, Pharmaceutical; Drug Design; Feeding Behavior; Humans; Inhibitory Concentration 50; Mice; Models, Chemical; Pyrroles; Rats; Receptors, Cannabinoid; Weight Gain	2009
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists. Journal of medicinal chemistry, 2009, Jul-23, Volume: 52, Issue:14 Topics: Animals; Anti-Obesity Agents; Body Weight; Cattle; Drug Design; Eating; Humans; Lipids; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship	2009
Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorganic & medicinal chemistry letters, 2010, Jan-15, Volume: 20, Issue:2 Topics: Amides; Animals; Anti-Obesity Agents; Blood-Brain Barrier; Body Weight; Drug Inverse Agonism; Mice; Obesity; Piperidines; Protein Binding; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship	2010
Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists. Bioorganic & medicinal chemistry letters, 2011, Aug-15, Volume: 21, Issue:16 Topics: Aminoimidazole Carboxamide; Animals; Body Weight; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred C57BL; Molecular Structure; Pyrazoles; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship	2011
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY). Journal of medicinal chemistry, 2013, Mar-14, Volume: 56, Issue:5 Topics: Amides; Animals; Anti-Obesity Agents; Body Weight; Eating; Ethanolamines; Female; Hypothalamus; Mice; Mice, Inbred C57BL; Mice, Obese; Neuropeptide Y; Nuclear Magnetic Resonance, Biomolecular; Oleic Acids; Pro-Opiomelanocortin; Valine	2013
Structural modifications in the distal, regulatory region of histamine H European journal of medicinal chemistry, 2021, Mar-05, Volume: 213 Topics: Animals; Anti-Obesity Agents; Body Weight; Dose-Response Relationship, Drug; Female; Histamine H3 Antagonists; Humans; Imidazoles; Ligands; Models, Molecular; Piperazine; Piperidines; Protein Binding; Rats, Wistar; Receptors, Histamine H3; Regulatory Sequences, Nucleic Acid; Structure-Activity Relationship	2021
Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB Journal of medicinal chemistry, 2022, 02-10, Volume: 65, Issue:3 Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Cannabinoid Receptor Antagonists; Diet, High-Fat; Drug Inverse Agonism; Hydrophobic and Hydrophilic Interactions; Male; Mice, Inbred C57BL; Molecular Structure; Obesity; Pyrazoles; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship	2022
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:11 Topics: Animals; Body Weight; Diet; Drug Inverse Agonism; Incretins; Liraglutide; Mice; Obesity; Receptors, Cannabinoid; Rimonabant; Weight Loss	2023
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, May-04, Volume: 50, Issue:6 Topics: Animals; Blood Glucose; Body Weight; Calcium Channels; Calcium Channels, L-Type; Cannabinoid Receptor Antagonists; Diet, High-Fat; Glucose Intolerance; Insulin Resistance; Male; Mice, Inbred C57BL; Models, Animal; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2017
A behavioral and pharmacological characterization of palatable diet alternation in mice. Pharmacology, biochemistry, and behavior, 2017, Volume: 163 Topics: Animals; Body Weight; Diet; Energy Intake; Feeding Behavior; Male; Mice; Mice, Inbred C57BL; Naltrexone; Piperazines; Piperidines; Pyrazoles; Rimonabant; Taste	2017
Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders. CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:6 Topics: Animals; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Rimonabant; RNA, Messenger; Stress, Psychological; Tacrolimus Binding Proteins; Tirapazamine	2018
Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity. Biochemistry. Biokhimiia, 2018, Volume: 83, Issue:10 Topics: Adipose Tissue; Administration, Oral; Animals; Body Weight; Cannabinoid Receptor Antagonists; Carnitine O-Palmitoyltransferase; Cholesterol; Diet, High-Fat; Leptin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Obesity; PPAR alpha; Receptor, Cannabinoid, CB1; Rimonabant	2018
Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. Physiology & behavior, 2019, 02-01, Volume: 199 Topics: Animals; Body Weight; Cannabinoid Receptor Antagonists; Eating; Endotoxemia; Inflammation; Insulin Resistance; Lipopolysaccharides; Liver; Male; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2019
The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food. Addiction biology, 2014, Volume: 19, Issue:5 Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Cannabinoid Receptor Antagonists; Compulsive Behavior; Corpus Striatum; Feeding Behavior; Food Preferences; Hypothalamic Area, Lateral; Male; Nucleus Accumbens; Piperidines; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Risk-Taking; Ventromedial Hypothalamic Nucleus	2014
NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacological research, 2013, Volume: 74 Topics: Animals; Anti-Obesity Agents; Benzoxepins; Body Weight; Cannabinoid Receptor Antagonists; Diet, High-Fat; Fatty Acid Synthases; Glucokinase; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Pyruvate Kinase; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Symporters	2013
Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:12 Topics: Amygdala; Animals; Anorexia; Anti-Obesity Agents; Anxiety; Arachidonic Acids; Body Weight; Cannabinoid Receptor Antagonists; Corticosterone; Diet; Dietary Sucrose; Endocannabinoids; Female; Glycerides; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant	2013
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PloS one, 2013, Volume: 8, Issue:7 Topics: Adiposity; Animals; Basal Metabolism; Bile Acids and Salts; Body Weight; Caloric Restriction; Diet; Drug Therapy, Combination; Fatty Acids; Fatty Liver; Feeding Behavior; Fibroblast Growth Factors; Gene Expression Regulation; Hepatocytes; Insulin; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oligonucleotides, Antisense; Oxidation-Reduction; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Fibroblast Growth Factor, Type 4; Rimonabant	2013
Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. American journal of physiology. Endocrinology and metabolism, 2014, Feb-15, Volume: 306, Issue:4 Topics: Adiponectin; Adiposity; Animals; Body Weight; Cannabinoid Receptor Antagonists; Diet, High-Fat; Energy Intake; Fatty Liver; Leptin; Lipid Metabolism; Lipids; Liver; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2014
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms	2014
Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. Endocrinology, 2015, Volume: 156, Issue:4 Topics: Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Antagonists; Endocannabinoids; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2015
The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia. Neuroscience letters, 2016, Sep-06, Volume: 630 Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain Ischemia; Cannabinoid Receptor Antagonists; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stroke	2016
[The endocannabinoid system]. Praxis, 2008, Apr-02, Volume: 97, Issue:7 Topics: Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Europe; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2008
Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse (New York, N.Y.), 2008, Volume: 62, Issue:9 Topics: Age Factors; Animals; Autoradiography; Body Weight; Cannabinoid Receptor Modulators; Eating; Food Deprivation; Hyperphagia; Leptin; Limbic System; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Receptors, Leptin; Rimonabant; Tritium; Up-Regulation	2008
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes, 2008, Volume: 57, Issue:11 Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Body Weight; Chromatography, Liquid; Dietary Fats; Eating; Fatty Acid Synthases; Glucose Clamp Technique; Lipid Metabolism; Lipoprotein Lipase; Male; Mass Spectrometry; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; Triglycerides	2008
Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:11 Topics: Adiponectin; Animals; Body Weight; Cholesterol; Disease Models, Animal; Eating; Fatty Acids, Nonesterified; Glycerol; Lipids; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Thinness; Triglycerides	2008
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. The American journal of pathology, 2008, Volume: 173, Issue:4 Topics: Actins; Animals; Apolipoprotein A-I; Body Weight; Cells, Cultured; Diet; Disease Models, Animal; Fatty Liver; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Organ Size; Piperidines; Pyrazoles; Rimonabant	2008
[Residual risk in cardiovascular prevention]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Atherosclerosis; Blood Pressure; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Humans; Hypolipidemic Agents; Kaplan-Meier Estimate; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Smoking Cessation; Thiazolidines; Time Factors	2008
Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. Behavioural pharmacology, 2008, Volume: 19, Issue:7 Topics: Animals; Appetitive Behavior; Body Weight; Dose-Response Relationship, Drug; Feeding Behavior; Male; Motivation; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Reinforcement Schedule; Rimonabant; Sucrose; Taste	2008
Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. The Journal of biological chemistry, 2009, Jan-16, Volume: 284, Issue:3 Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Body Weight; Eating; Glucose; Insulin Resistance; Liver; Mice; Mice, Knockout; Mice, Obese; Muscle, Skeletal; Piperidines; Pyrazoles; Rimonabant	2009
Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice. PloS one, 2008, Volume: 3, Issue:10 Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Body Weight; Cannabinoid Receptor Antagonists; Dietary Fats; Extracellular Matrix; Gene Expression Regulation; Insulin; Leptin; Lipoproteins, VLDL; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Transcription, Genetic	2008
The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:2 Topics: Adipose Tissue, Brown; Animals; Body Weight; Cannabinoids; Central Nervous System; Eating; Energy Metabolism; Ion Channels; Male; Mitochondrial Proteins; Models, Animal; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; RNA, Messenger; Thermogenesis; Uncoupling Protein 1	2009
ADAGIO-Lipids gives promises but faces the setbacks. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3 Topics: Adiponectin; Adiposity; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Humans; Insulin; Intra-Abdominal Fat; Lipids; Liver; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome	2009
Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 296, Issue:6 Topics: Animals; Body Weight; Dietary Fats; Dogs; Eating; Energy Metabolism; Intra-Abdominal Fat; Magnetic Resonance Imaging; Male; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Subcutaneous Fat, Abdominal	2009
Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats. European journal of pharmacology, 2009, Aug-15, Volume: 616, Issue:1-3 Topics: Animals; Body Weight; Cannabinoid Receptor Modulators; Cattle; Eating; Fasting; Glucose; Glucose Tolerance Test; Homeostasis; Hyperinsulinism; Hyperplasia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Pancreas; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant; Time Factors	2009
Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. Pharmacology, biochemistry, and behavior, 2009, Volume: 94, Issue:1 Topics: Aging; Analysis of Variance; Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Modulators; Conditioning, Operant; Dose-Response Relationship, Drug; Endocannabinoids; Feeding Behavior; Female; Fetal Nutrition Disorders; Glycerides; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Sucrose; Time Factors	2009
Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. International journal of obesity (2005), 2010, Volume: 34, Issue:2 Topics: Animals; Body Weight; Cannabinoids; Dietary Fats; Energy Metabolism; Fatty Acids; Fish Oils; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2010
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:11 Topics: Adipokines; Adiponectin; Adipose Tissue; Adipose Tissue, White; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Down-Regulation; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Animal; Nicotinamide Phosphoribosyltransferase; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Tumor Necrosis Factor-alpha	2009
Pharmacotherapy for obesity. British journal of clinical pharmacology, 2009, Volume: 68, Issue:6 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors	2009
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. Journal of neurochemistry, 2010, Volume: 112, Issue:5 Topics: Amides; Analysis of Variance; Animals; Autoradiography; Benzoxazines; Body Weight; Brain; Cyclohexanols; Diet Fads; Disease Models, Animal; Eating; Female; Guanosine 5'-O-(3-Thiotriphosphate); International Cooperation; Morpholines; Naphthalenes; Obesity; Piperidines; Protein Binding; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Isotopes; Time Factors; Tomography Scanners, X-Ray Computed; Tritium; Whole Body Imaging	2010
FAAH deficiency promotes energy storage and enhances the motivation for food. International journal of obesity (2005), 2010, Volume: 34, Issue:3 Topics: Adiposity; Amidohydrolases; Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Modulators; Conditioning, Operant; Darkness; Dietary Fats; Eating; Endocannabinoids; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motivation; Obesity; Oleic Acids; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Triglycerides	2010
CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes, 2010, Volume: 59, Issue:4 Topics: Adiponectin; Adipose Tissue; Animal Feed; Animals; Apolipoproteins A; Apolipoproteins B; Body Weight; Cannabinoid Receptor Antagonists; Diet; Fatty Liver; Gene Expression Regulation; Liver; Mice; Mice, Obese; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sucrose	2010
TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity. American journal of hypertension, 2010, Volume: 23, Issue:7 Topics: Animals; Anti-Obesity Agents; Antibodies, Monoclonal; Blood Pressure; Body Weight; Brain-Derived Neurotrophic Factor; Diet; Dietary Fats; Hypertension; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, trkB; Rimonabant; Telemetry; Weight Loss	2010
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat. European journal of pharmacology, 2010, Jul-10, Volume: 637, Issue:1-3 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Male; Neurons; Peripheral Nerves; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Skin; Streptozocin; Time Factors; Tumor Necrosis Factor-alpha	2010
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:2 Topics: Animals; Biomarkers; Blood Vessels; Body Weight; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Inflammation; Insulin Resistance; Intestinal Mucosa; Kidney Diseases; Kidney Glomerulus; Lipid Metabolism; Male; Metabolic Syndrome; Myocardial Ischemia; Piperidines; Prediabetic State; Pyrazoles; Rats; Rats, Mutant Strains; Renal Circulation; Rimonabant; Sclerosis; Thrombosis	2010
The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1 Topics: Adipose Tissue; Animals; Animals, Newborn; Body Weight; Drug Evaluation, Preclinical; Epididymis; Female; Hormones; Male; Metabolic Diseases; Mice; Overweight; Piperidines; Pregnancy; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological; Time Factors	2011
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes? The Journal of clinical investigation, 2010, Volume: 120, Issue:8 Topics: Animals; Appetite Regulation; Body Weight; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2010
Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. European journal of pharmacology, 2010, Nov-10, Volume: 646, Issue:1-3 Topics: Adipocytes; Adipose Tissue; Animals; Body Weight; Eating; Female; Lipolysis; Male; Microdialysis; Norepinephrine; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors	2010
Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats. Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:5 Topics: Acetylcholine; Animals; Aorta, Thoracic; Body Weight; Endothelium, Vascular; Nitric Oxide Synthase Type II; Nitrobenzenes; Obesity; Phenylephrine; Piperidines; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides; Tumor Necrosis Factor-alpha; Vasodilation; Vasodilator Agents	2010
Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:1 Topics: Alcohol Drinking; Alcoholism; Animals; Body Weight; Central Nervous System Depressants; Dopamine; Ethanol; Male; Mice; Mice, Knockout; Motor Activity; Neostriatum; Nucleus Accumbens; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2; Rimonabant; Synaptic Transmission; Time Factors; Up-Regulation	2011
Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behavioural brain research, 2011, Mar-01, Volume: 217, Issue:2 Topics: Analysis of Variance; Animals; Body Weight; Diet; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Leptin; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Signal Transduction	2011
Plasma and liver lipidomics response to an intervention of rimonabant in ApoE3Leiden.CETP transgenic mice. PloS one, 2011, Volume: 6, Issue:5* Topics: Animals; Apolipoprotein E3; Body Weight; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Feeding Behavior; Humans; Lipids; Liver; Mice; Mice, Transgenic; Piperidines; Pyrazoles; Rimonabant; Triglycerides	2011
The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:10 Topics: Adiponectin; Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Body Weight; Central Nervous System; Cholesterol; Diet, High-Fat; Energy Intake; Gastrointestinal Transit; Hypothermia; Insulin; Leptin; Mice; Mice, Knockout; Mice, Transgenic; MicroRNAs; Mutation; Obesity; Peripheral Nervous System; Phenotype; Piperidines; Promoter Regions, Genetic; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides	2011
CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice. Endocrinology, 2011, Volume: 152, Issue:10 Topics: Affect; Animals; Behavior, Animal; Body Weight; Brain; Eating; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Opioid, kappa; Receptors, Opioid, mu; Rimonabant; Signal Transduction	2011
Blocking the postpartum mouse dam's CB1 receptors impairs maternal behavior as well as offspring development and their adult social-emotional behavior. Behavioural brain research, 2012, Jan-15, Volume: 226, Issue:2 Topics: Animals; Animals, Newborn; Animals, Outbred Strains; Behavior, Animal; Body Temperature; Body Weight; Emotions; Female; Male; Maternal Behavior; Maze Learning; Mice; Piperidines; Postpartum Period; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Social Behavior; Vocalization, Animal	2012
Cannabinoid CB₁ receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats. Neuropharmacology, 2012, Volume: 63, Issue:1 Topics: Animals; Anorexia Nervosa; Body Weight; Brain Stem; Cell Count; Corticosterone; Corticotropin-Releasing Hormone; Disease Models, Animal; Eating; Endotoxemia; Gene Expression Regulation; Hypothalamus; Lipopolysaccharides; Male; Melanocyte-Stimulating Hormones; Microdialysis; Neurons; Oncogene Proteins v-fos; Piperidines; Pyrazoles; Radioimmunoassay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Time Factors; Tyrosine 3-Monooxygenase	2012
Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE3Leiden.CETP mice. PloS one, 2012, Volume: 7, Issue:1* Topics: 3T3-L1 Cells; Adipocytes; Animals; Anticholesteremic Agents; Apolipoprotein E3; Biochemistry; Body Weight; Cholesterol Ester Transfer Proteins; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Female; Lipid Metabolism; Lipids; Metabolic Networks and Pathways; Metabolomics; Mice; Mice, Transgenic; Piperidines; Pyrazoles; Rimonabant	2012
Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters. Journal of neuroendocrinology, 2012, Volume: 24, Issue:7 Topics: Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Modulators; Cricetinae; Drug Evaluation, Preclinical; Eating; Endocannabinoids; Energy Metabolism; Female; Intra-Abdominal Fat; Male; Phodopus; Photoperiod; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction	2012
Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. International journal of obesity (2005), 2013, Volume: 37, Issue:2 Topics: Adipose Tissue, Brown; Adipose Tissue, White; Affect; Animals; Anti-Obesity Agents; Body Weight; Drug Therapy, Combination; Hypothalamic Hormones; Lipolysis; Male; Melanins; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Physical Conditioning, Animal; Piperidines; Pituitary Hormones; Pyrazoles; Rimonabant; Thermogenesis; Weight Loss	2013
Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats. Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:6 Topics: Adiposity; Animals; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Lactones; Male; Obesity; Orlistat; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Weight Gain	2012
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behavioural brain research, 2012, Oct-01, Volume: 234, Issue:2 Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides	2012
Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, Jul-25, Volume: 32, Issue:30 Topics: Animals; Body Weight; Diet, High-Fat; Eating; Food Deprivation; Gastrointestinal Motility; Homeostasis; Hyperphagia; Mice; Mice, Transgenic; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Vagus Nerve	2012
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology, 2013, Volume: 226, Issue:2 Topics: Animals; Appetite; Behavior, Animal; Body Weight; Cannabinoid Receptor Antagonists; Compulsive Behavior; Dose-Response Relationship, Drug; Feeding Behavior; Food; Grooming; Locomotion; Male; Naloxone; Narcotic Antagonists; Piperidines; Pruritus; Pyrazoles; Rats; Rimonabant	2013
Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus. Regulatory peptides, 2013, Mar-10, Volume: 182 Topics: Adaptation, Physiological; Animals; Anorexia; Body Weight; Cannabinoid Receptor Antagonists; Eating; Hypothalamus; Male; Neuropeptides; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger	2013
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American journal of physiology. Regulatory, integrative and comparative physiology, 2003, Volume: 284, Issue:2 Topics: Animals; Binding Sites; Body Weight; Diet; Dietary Fats; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Insulin; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Time Factors	2003
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular pharmacology, 2003, Volume: 63, Issue:4 Topics: 3T3 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Body Weight; Cannabinoids; Cells, Cultured; Disease Models, Animal; Gene Expression; Hyperinsulinism; Intercellular Signaling Peptides and Proteins; Male; Mice; Obesity; Piperidines; Protein Biosynthesis; Proteins; Pyrazoles; Rats; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; RNA, Messenger	2003
Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Brain research. Molecular brain research, 2003, Jun-10, Volume: 114, Issue:2 Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Benzoxazines; Body Weight; Brain; Cannabinoids; Disease Models, Animal; Female; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Male; Morpholines; Naphthalenes; Nerve Degeneration; Neurons; Neuroprotective Agents; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant	2003
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:4 Topics: Animals; Body Weight; Diet; Dietary Fats; Eating; Energy Intake; Energy Metabolism; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Leptin; Recombinant Proteins; Rimonabant; Thinness	2004
[Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Appetite; Body Weight; Brain; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2004
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International journal of obesity (2005), 2005, Volume: 29, Issue:2 Topics: Animals; Blood Glucose; Body Weight; Eating; Energy Metabolism; Female; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Oxygen Consumption; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis; Tissue Culture Techniques	2005
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain research bulletin, 2005, Mar-15, Volume: 65, Issue:2 Topics: Animals; Body Weight; Cannabinoid Receptor Modulators; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Eating; Endocannabinoids; Feeding and Eating Disorders; Female; Food Deprivation; Glycerides; Mice; Mice, Inbred C57BL; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Species Specificity; Weight Gain	2005
Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behavioural pharmacology, 2005, Volume: 16, Issue:5-6 Topics: Analysis of Variance; Animals; Body Weight; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Drug Tolerance; Eating; Feeding Behavior; Hyperphagia; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors	2005
Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. European journal of pharmacology, 2006, Jan-13, Volume: 530, Issue:1-2 Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drinking; Drinking Behavior; Dronabinol; Feeding Behavior; Injections, Intraperitoneal; Male; Motor Activity; Piperidines; Pyrans; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors	2006
The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacology, biochemistry, and behavior, 2006, Volume: 84, Issue:2 Topics: Adiponectin; Animals; Body Weight; Dietary Fats; Eating; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant	2006
The effects of anorexic drugs on free-fed rats responding under a second-order FI15-min (FR10:S) schedule for high incentive foods. Behavioural pharmacology, 2007, Volume: 18, Issue:1 Topics: Animals; Appetite; Appetite Depressants; Appetitive Behavior; Body Weight; Dextroamphetamine; Dose-Response Relationship, Drug; Energy Intake; Extinction, Psychological; Feeding Behavior; Fenfluramine; Male; Motivation; Naloxone; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Reinforcement Schedule; Rimonabant	2007
Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. British journal of pharmacology, 2007, Volume: 150, Issue:5 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Arthritis, Experimental; Body Weight; Edema; Female; Freund's Adjuvant; Hot Temperature; Hyperalgesia; Inflammation; Joints; Nitric Oxide; Obesity; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Rats; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Touch	2007
Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Apr-13, Volume: 31, Issue:3 Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Body Weight; Cannabinoid Receptor Modulators; Carbamates; Cyclohexanes; Cyclohexanols; Dose-Response Relationship, Drug; Drinking Behavior; Drug Interactions; Endocannabinoids; Food Deprivation; Food Preferences; Male; Mice; Mice, Inbred ICR; Phenols; Piperidines; Pyrazoles; Restraint, Physical; Reward; Rimonabant; Stress, Psychological; Sucrose; Time Factors; Water Deprivation	2007
Cardiometabolic risk modification: current trends and emerging therapies. JAAPA : official journal of the American Academy of Physician Assistants, 2006, Volume: Suppl Cardiometabolic Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain	2006
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British journal of pharmacology, 2007, Volume: 152, Issue:5 Topics: Animals; Benzoxazines; Body Weight; Camphanes; Cannabinoids; Catalepsy; Dose-Response Relationship, Drug; Hindlimb; Hyperesthesia; Injections, Intraperitoneal; Injections, Spinal; Male; Morphine; Morpholines; Naphthalenes; Neuralgia; Pain Measurement; Pain Threshold; Physical Stimulation; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Thermosensing; Vincristine	2007
Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatric research, 2007, Volume: 62, Issue:5 Topics: Animals; Animals, Newborn; Body Temperature; Body Weight; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug; Eating; Failure to Thrive; Female; Injections, Subcutaneous; Male; Mice; Milk; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors	2007
Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats. Psychopharmacology, 2008, Volume: 198, Issue:4 Topics: Analysis of Variance; Animals; Body Weight; Cues; Injections, Intraperitoneal; Male; Motor Activity; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant	2008
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney international, 2007, Volume: 72, Issue:11 Topics: Adiponectin; Animals; Body Weight; Disease Models, Animal; Eating; Kidney; Kidney Failure, Chronic; Lipids; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Survival Analysis	2007
Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia. Journal of neurochemistry, 2007, Volume: 103, Issue:6 Topics: Analgesia; Analgesics, Opioid; Animals; Behavior, Animal; Body Weight; Hot Temperature; Immunohistochemistry; Male; Mice; Morpholines; Motor Activity; Pain Measurement; Piperidines; Proto-Oncogene Proteins c-fos; Psychomotor Performance; Pyrazoles; Reaction Time; Receptor, Cannabinoid, CB1; Receptors, Opioid, kappa; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Spinal Cord; Synaptic Transmission	2007
Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. International journal of obesity (2005), 2008, Volume: 32, Issue:5 Topics: Animals; Body Weight; Energy Metabolism; Male; Mice; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Regression Analysis; Rimonabant; Satiety Response; Stereotyped Behavior	2008
Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology, 2008, Volume: 149, Issue:5 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Candy; Diet; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Liver Glycogen; Male; Photoperiod; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Time Factors; Weight Loss	2008
Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiology & behavior, 2008, Jun-09, Volume: 94, Issue:3 Topics: Analgesics, Opioid; Analysis of Variance; Animals; Appetite; Behavior, Animal; Body Weight; Cannabinoids; Eating; Grooming; Locomotion; Naloxone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Reaction Time; Rimonabant; Time Factors	2008
Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 295, Issue:1 Topics: Animals; Appetite Depressants; Body Weight; Diet; Drug Administration Schedule; Eating; Energy Intake; Female; Food Preferences; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant	2008
Rimonabant in rats with a metabolic syndrome: good news after the depression. British journal of pharmacology, 2008, Volume: 154, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant	2008
Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 278, Issue:3 Topics: Animals; Body Weight; Dronabinol; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome	1996
Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. British journal of pharmacology, 1998, Volume: 125, Issue:7 Topics: Analysis of Variance; Animals; Body Temperature; Body Weight; Conditioning, Psychological; Cyclic AMP; Dronabinol; Drug Interactions; Hallucinogens; Hypothermia; In Vitro Techniques; Male; Mice; Motivation; Narcotics; Pain Measurement; Piperidines; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome	1998
Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Dec-15, Volume: 20, Issue:24 Topics: Acute Disease; Analysis of Variance; Animals; Autoradiography; Behavior, Animal; Body Temperature; Body Weight; Brain; Chronic Disease; Dronabinol; Drug Tolerance; Enkephalins; Hyperalgesia; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Protein Precursors; Psychotropic Drugs; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome	2000
Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. European journal of pharmacology, 2001, Mar-23, Volume: 416, Issue:1-2 Topics: Animals; Behavior, Animal; Benzoxazines; Body Weight; Cannabinoids; Dose-Response Relationship, Drug; Male; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Substance Withdrawal Syndrome; Time Factors	2001
Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:9 Topics: Animals; Body Weight; Drinking; Ethanol; Kinetics; Male; Motor Activity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Self Administration	2001